Medical Developments International Ltd represents the values of innovation, patient care, and commitment to excellence. With a corporate philosophy centered around improving health outcomes, they strive to develop and provide high-quality medical solutions. By continually researching and investing in cutting-edge technology, Medical Developments International Ltd aims to revolutionize healthcare and create effective treatments for various conditions. Their commitment to integrity, accountability, and ethical practices makes them a trusted leader in the industry. With a focus on improving the well-being of patients, Medical Developments International Ltd is dedicated to delivering innovative solutions that enhance the quality of life for individuals worldwide.

Medical Developments International Ltd (MDI) is primarily present in several countries and regions. The company has a global footprint with significant operations in Australia, New Zealand, and the United States. As an internationally recognized healthcare company, MDI caters to a wide range of markets worldwide, including Europe, Asia, and the Middle East. With its innovative medical solutions and strong market presence, Medical Developments International Ltd continues to expand its reach to meet the growing demand for its products and services across various countries and regions.

Medical Developments International Ltd has achieved significant milestones since its inception. The company has successfully developed and commercialized innovative medical solutions, positioning itself as a global leader in emergency medical products. Notably, Medical Developments International Ltd has received regulatory approvals for their flagship product, Penthrox, across various countries, including the EU, UK, Australia, New Zealand, and Canada. The company has also forged partnerships with renowned distributors, enabling them to expand their market presence and increase sales. Additionally, Medical Developments International Ltd has continuously invested in research and development to enhance their product portfolio, ensuring they remain at the forefront of medical advancements.

Medical Developments International Ltd is a leading Australian pharmaceutical company specializing in the development and distribution of innovative medical devices and drugs. Founded in 1971, Medical Developments International Ltd has consistently demonstrated a commitment to improving patient outcomes through advanced healthcare products. With a strong focus on research and development, the company has successfully introduced breakthrough solutions in the areas of pain management, respiratory care, and emergency medicine. Over the years, Medical Developments International Ltd has garnered a solid reputation for delivering high-quality and effective medical solutions to healthcare professionals worldwide.

The main competitors of Medical Developments International Ltd in the market include companies such as Pfizer, Johnson & Johnson, and GlaxoSmithKline.

Medical Developments International Ltd primarily operates in the healthcare industry.

The business model of Medical Developments International Ltd is focused on developing and commercializing innovative pharmaceutical products. With a strong emphasis on research and development, the company aims to improve healthcare by offering safe and effective medical solutions. Medical Developments International Ltd strives to collaborate with healthcare professionals and institutions to deliver high-quality and affordable medical products. Through its commitment to innovation and partnership, the company has established itself as a leading player in the healthcare industry, continuously working towards improving patient outcomes and overall healthcare delivery.

Medical Developments International KGV ir -4,62.

Medical Developments International KUV ir 0,71.

AlleAktien kvalitātes vērtējums Medical Developments International ir 5/10.

gaidāmā Medical Developments International apgrozījums ir 51,61 milj. AUD.

gaidāmā Medical Developments International peļņa ir -7,97 milj. AUD.

Medical Developments International Ltd is an Australian company that offers sustainable solutions in the field of lifesaving, pain relief, and inhalation therapy. The company develops, manufactures, and distributes inhalers, pain relief products, and medical devices. In the lifesaving sector, the company offers the emergency inhalator system Penthrox. This system is used in the treatment of acute pain and injuries such as bone fractures and burns. The Penthrox system is easy to handle and can be quickly deployed by paramedics and emergency physicians on site. This technology is ideal for the military, sports events, and other public gatherings. The company also offers a wide range of pain relief products. The pain reliever Green whistle is a sustainable, hydrogen-based analgesic used in pain therapy. It is easy to use, safe, and effective. The device is ideal for use in hospitals, pain therapy, and palliative care. Inhalation therapy is the company's third business area. The company offers a wide range of inhalation devices specifically developed for people with asthma or other respiratory diseases. With the nebulizer "Nebu-Tech," patients receive precise dosage of the medication, which effectively reaches the lungs. The company has also developed solutions for kindergarten and school medicine to improve the treatment of children and students with asthma. Medical Developments International Ltd places special emphasis on sustainability and environmental friendliness. The company invests in research and development of sustainable technologies and materials to provide eco-friendly products and services. The products are designed for long-term use and can be easily recycled. The well-being of the patient is also a priority in production. No animal components are used, and high standards of quality and safety are ensured. In summary, Medical Developments International Ltd offers a wide range of products that can be used to save lives, alleviate pain, and treat respiratory diseases. The company is focused on sustainability and environmental friendliness and places special emphasis on quality and safety. With the marketing of high-quality products, the company aims to improve the lives of its customers.

Medical Developments International izmaksā dividendes 0 AUD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Medical Developments International vai uzņēmums nedod dividendes.

Medical Developments International ISIN ir AU000000MVP2.

Medical Developments International WKN ir A0BLXB.

Medical Developments International simbols ir MVP.AX.

Pēdējo 12 mēnešu laikā Medical Developments International maksāja dividendes 0,03 AUD apmērā. Tas atbilst aptuveni 6,65 % dividendes ražībai. Nākamajos 12 mēnešos Medical Developments International plāno maksāt dividendes 0 AUD apmērā.

Medical Developments International pašreizējā dividendu rentabilitāte ir 6,65 %.

Medical Developments International maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos septembris, aprīlis, oktobris, aprīlis.

Medical Developments International pēdējo 2 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 AUD. Tas atbilst dividendes ražībai 0 %.

Medical Developments International tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Medical Developments International apmērā 0,028 AUD, kas tika izmaksāta 17.04.2020., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 5.03.2020..

Pēdējās dividendes izmaksa notika 17.04.2020..

Gadā 2024, Medical Developments International izmaksāja 0 AUD dividendes.

Medical Developments International dividendes tiek izmaksātas AUD.